What roles do serotonin, dopamine, noradrenaline, and muscarinic receptors play in the pathophysiology of nausea and vomiting?

Neurotransmitter Roles in Nausea and Vomiting

Serotonin (5-HT3) and dopamine receptors are the principal neuroreceptors driving the emetic response, while acetylcholine (muscarinic) receptors mediate vomiting through the vestibular centers, and noradrenaline (via alpha-2 adrenergic receptors) can activate the chemoreceptor trigger zone to initiate emesis. 1, 2

Primary Mechanisms

Serotonin (5-HT3 Receptors)

• Located in: Chemoreceptor trigger zone (CTZ), vomiting center, and gastrointestinal tract 1, 2
• Activation mechanism: Chemotherapeutic agents or their metabolites directly activate these receptors 1
• Clinical significance: This is why 5-HT3 antagonists (ondansetron, granisetron, palonosetron) form the backbone of antiemetic therapy for chemotherapy-induced nausea and vomiting 1
• Peripheral role: Serotonergic receptors in the GI tract contribute to the motor correlates of vomiting 3

Dopamine (D2 Receptors)

• Located in: Chemoreceptor trigger zone primarily 1, 2
• Function: Dopamine D2 receptors mediate vomiting and its gastrointestinal motor correlates through the emetic central pattern generator 3
• Clinical application: Dopamine antagonists (metoclopramide, haloperidol, prochlorperazine) are particularly effective for CTZ-mediated nausea and impaired GI function 4
• Important caveat: Dopamine receptor agonists used for Parkinson's disease commonly cause nausea and vomiting as side effects 5

Muscarinic (Acetylcholine) Receptors

• Located in: Vomiting center and vestibular centers of the brain 1, 2
• Specific role: Peripheral muscarinic receptors mediate the retrograde giant contraction (RGC) component of vomiting's GI motor correlates 3
• Clinical context: Muscarinic antagonists (scopolamine) are particularly effective for motion sickness and vestibular-mediated nausea 6, 7
• Mechanism: Atropine blocks only the RGC, while nicotinic blockade (hexamethonium) blocks all jejunoileal motor responses 3

Noradrenaline (Alpha-2 Adrenergic Receptors)

• Located in: Chemoreceptor trigger zone 8
• Activation: Alpha-2 adrenergic receptor agonists (clonidine, UK-14304) can initiate vomiting and its GI motor correlates 8
• Cross-talk: These responses are modulated by 5-HT2 serotonergic, muscarinic cholinergic, and opiate receptors within the CNS 8
• Clinical note: Peripheral adrenergic receptors do NOT mediate the GI motor correlates of vomiting 8

Integrated Pathway Understanding

No single final common pathway for emesis exists 1, which explains why:

• Single-agent antiemetics cannot provide complete protection across all emetic phases 1
• Combination therapy targeting multiple receptors is more effective than monotherapy, especially in high-risk patients 6
• Different antiemetic classes work synergistically when blocking different neuronal pathways 1, 9

Receptor Interactions

The complexity increases because:

• Opioid receptors mediate tonic inhibition of emetic responses 3
• 5-HT2 serotonergic receptors (distinct from 5-HT3) participate in controlling emesis activated by alpha-2 adrenergic agonists 8
• Nicotinic cholinergic receptors (in addition to muscarinic) mediate GI motor correlates peripherally 3

Clinical Algorithm for Antiemetic Selection

Based on the receptor mechanisms 1:

1. For chemotherapy-induced emesis: Start with 5-HT3 antagonist + dexamethasone ± NK-1 antagonist (aprepitant)
2. Add dopamine antagonists (metoclopramide, haloperidol) for breakthrough emesis or CTZ-mediated nausea 1
3. For vestibular/motion sickness: Use muscarinic antagonists (scopolamine) or H1 antagonists 6, 7
4. For refractory cases: Combine agents from different receptor classes to achieve synergistic blockade 1

Critical pitfall: Switching between 5-HT3 antagonists when one fails is unlikely to be effective since they target the same receptor 1. Instead, add agents targeting different receptors (dopamine, NK-1, muscarinic).